Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. ・PBYI stock has ...

Shares of the biotech stock fell through their 50-day and 200-day moving averages in volume that was tracking 4,000% above ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

This stock is a great choice for cautious and aggressive investors.

The bank's list of highest-conviction stock picks for 2026 spans numerous sectors and features names including Pepsi and GM.

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google.

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.